Modified Live Vaccine Market Report – Research, Industry Analysis Reports and Market Demands

Global Modified Live Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Modified Live Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Monovalent Live Attenuated Vaccines
- 1.3.3 Multivalent Live Attenuated Vaccines
- 1.3.4 Combination Live Attenuated Vaccines
1.4 Market Analysis by Pathogen
- 1.4.1 Overview: Global Modified Live Vaccine Consumption Value by Pathogen: 2021 Versus 2025 Versus 2032
- 1.4.2 Viral Live Attenuated Vaccines
- 1.4.3 Bacterial Live Attenuated Vaccines
- 1.4.4 Parasitic Live Attenuated Vaccines
1.5 Market Analysis by Application
- 1.5.1 Overview: Global Modified Live Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.5.2 Livestock
- 1.5.3 Poultry
- 1.5.4 Companion Animals
- 1.5.5 Others
1.6 Global Modified Live Vaccine Market Size & Forecast
- 1.6.1 Global Modified Live Vaccine Consumption Value (2021 & 2025 & 2032)
- 1.6.2 Global Modified Live Vaccine Sales Quantity (2021-2032)
- 1.6.3 Global Modified Live Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Modified Live Vaccine by Manufacturer

3.1 Global Modified Live Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global Modified Live Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global Modified Live Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Modified Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Modified Live Vaccine Manufacturer Market Share in 2025
- 3.4.3 Top 6 Modified Live Vaccine Manufacturer Market Share in 2025
3.5 Modified Live Vaccine Market: Overall Company Footprint Analysis
- 3.5.1 Modified Live Vaccine Market: Region Footprint
- 3.5.2 Modified Live Vaccine Market: Company Product Type Footprint
- 3.5.3 Modified Live Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Modified Live Vaccine Market Size by Region
- 4.1.1 Global Modified Live Vaccine Sales Quantity by Region (2021-2032)
- 4.1.2 Global Modified Live Vaccine Consumption Value by Region (2021-2032)
- 4.1.3 Global Modified Live Vaccine Average Price by Region (2021-2032)
4.2 North America Modified Live Vaccine Consumption Value (2021-2032)
4.3 Europe Modified Live Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific Modified Live Vaccine Consumption Value (2021-2032)
4.5 South America Modified Live Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa Modified Live Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Modified Live Vaccine Sales Quantity by Type (2021-2032)
5.2 Global Modified Live Vaccine Consumption Value by Type (2021-2032)
5.3 Global Modified Live Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Modified Live Vaccine Sales Quantity by Application (2021-2032)
6.2 Global Modified Live Vaccine Consumption Value by Application (2021-2032)
6.3 Global Modified Live Vaccine Average Price by Application (2021-2032)

7 North America

7.1 North America Modified Live Vaccine Sales Quantity by Type (2021-2032)
7.2 North America Modified Live Vaccine Sales Quantity by Application (2021-2032)
7.3 North America Modified Live Vaccine Market Size by Country
- 7.3.1 North America Modified Live Vaccine Sales Quantity by Country (2021-2032)
- 7.3.2 North America Modified Live Vaccine Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Modified Live Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe Modified Live Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe Modified Live Vaccine Market Size by Country
- 8.3.1 Europe Modified Live Vaccine Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Modified Live Vaccine Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Modified Live Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Modified Live Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Modified Live Vaccine Market Size by Region
- 9.3.1 Asia-Pacific Modified Live Vaccine Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Modified Live Vaccine Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Modified Live Vaccine Sales Quantity by Type (2021-2032)
10.2 South America Modified Live Vaccine Sales Quantity by Application (2021-2032)
10.3 South America Modified Live Vaccine Market Size by Country
- 10.3.1 South America Modified Live Vaccine Sales Quantity by Country (2021-2032)
- 10.3.2 South America Modified Live Vaccine Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Modified Live Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Modified Live Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Modified Live Vaccine Market Size by Country
- 11.3.1 Middle East & Africa Modified Live Vaccine Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Modified Live Vaccine Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Modified Live Vaccine Market Drivers
12.2 Modified Live Vaccine Market Restraints
12.3 Modified Live Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Modified Live Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Modified Live Vaccine
13.3 Modified Live Vaccine Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Modified Live Vaccine Typical Distributors
14.3 Modified Live Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Modified Live Vaccine market size was valued at US$ 552 million in 2025 and is forecast to a readjusted size of US$ 826 million by 2032 with a CAGR of 6.8% during review period.
In 2025, global Modified Live Vaccine approximately 22,364 k doses, with an average global market price of around US$ 24 per dose. Gross margin is about 47%. The cost is 13 usd. The Production is about 25,000 k doses. A Modified Live Vaccine is a type of live vaccine made from a pathogen that has been weakened or genetically modified to reduce its ability to cause disease while retaining limited replication capability. After administration, it can mimic natural infection and stimulate strong and long-lasting immune responses in animals. Modified live vaccines are widely used in disease prevention for swine, cattle, sheep, poultry, and companion animals. Compared with inactivated vaccines, they usually provide stronger and faster immunity with lower doses, but they require stricter control over storage, transportation, safety, and strain stability.
Modified live vaccines will develop toward improved safety, stability, and precision. As large-scale farming and animal disease prevention requirements continue to increase, manufacturers will focus more on attenuation stability, control of reversion-to-virulence risk, duration of immunity, and cross-protection capability. Genetic attenuation, reverse genetics, vector-based vaccines, and multivalent combination vaccines will become important R&D directions, enabling broader protection against multiple pathogens or serotypes and improving immune efficacy across swine, cattle, sheep, poultry, and companion animals. At the same time, cold-chain stability, freeze-drying processes, and mass administration methods such as spray, drinking water, and intranasal delivery will continue to improve, reducing vaccination costs and increasing efficiency in large-scale applications.
This report is a detailed and comprehensive analysis for global Modified Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Modified Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Modified Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Modified Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Modified Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Modified Live Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Modified Live Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zoetis, Ceva Santé Animale, Boehringer Ingelheim Animal Health, MSD Animal Health, Virbac, HIPRA, Vetoquinol, Phibro Animal Health, IDT Biologika, Vaxxinova, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Modified Live Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monovalent Live Attenuated Vaccines
Multivalent Live Attenuated Vaccines
Combination Live Attenuated Vaccines
Market segment by Pathogen
Viral Live Attenuated Vaccines
Bacterial Live Attenuated Vaccines
Parasitic Live Attenuated Vaccines
Market segment by Application
Livestock
Poultry
Companion Animals
Others
Major players covered
Zoetis
Ceva Santé Animale
Boehringer Ingelheim Animal Health
MSD Animal Health
Virbac
HIPRA
Vetoquinol
Phibro Animal Health
IDT Biologika
Vaxxinova
KBNP Inc.
China Pharmaceutical Group Animal Health Co., Ltd.
Jinyu Bio-technology Co., Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Modified Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Modified Live Vaccine, with price, sales quantity, revenue, and global market share of Modified Live Vaccine from 2021 to 2026.
Chapter 3, the Modified Live Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Modified Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Modified Live Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Modified Live Vaccine.
Chapter 14 and 15, to describe Modified Live Vaccine sales channel, distributors, customers, research findings and conclusion.

Buy now